Summary
This study is designed to demonstrate that a multimodal hyperspectral device (LuViva) is able
to segregate women with abnormal screening tests into Low and High risk groups for the
purpose of determining whether they require enhanced colposcopy and additional biopsies in
order to increase detection of CIN2+ cervical disease.